PriceTargets.com logo

Sartorius Stedim Biotech - SDMHF Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$224.44 As of 04/25/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SDMHF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sartorius Stedim Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SDMHF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SDMHF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Sartorius Stedim Biotech in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $224.44.

This chart shows the closing price for SDMHF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Sartorius Stedim Biotech. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/9/2023BarclaysInitiated CoverageEqual Weight
9/6/2023Jefferies Financial GroupInitiated CoverageBuy
1/23/2023Credit Suisse GroupInitiated CoverageNeutral
10/11/2022Morgan StanleyLower Target€465.00 ➝ €455.00
7/27/2022UBS GroupBoost Target€370.00 ➝ €420.00
7/22/2022JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight€550.00 ➝ €470.00
7/22/2022Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight€445.00 ➝ €465.00
6/22/2022HSBCInitiated CoverageBuy
5/16/2022UBS GroupUpgradeSell ➝ Buy
3/31/2022Morgan StanleyInitiated CoverageEqual Weight
1/28/2022Societe GeneraleUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.Boost Target€530.00 ➝ €550.00
11/11/2021UBS GroupReiterated RatingSell
10/21/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/1/2021Societe GeneraleDowngradeBuy ➝ Hold
7/26/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/6/2021Societe GeneraleUpgradeHold ➝ Buy
7/6/2021AlphaValueUpgradeSell
4/22/2021Societe GeneraleDowngradeBuy ➝ Hold
3/22/2021JPMorgan Chase & Co.Reiterated RatingOverweight
2/11/2021Societe GeneraleDowngradeBuy ➝ Hold
2/4/2021UBS GroupReiterated RatingSell
2/1/2021Berenberg BankReiterated RatingBuy
1/29/2021JPMorgan Chase & Co.Reiterated RatingOverweight
10/23/2020Berenberg BankReiterated RatingBuy
10/22/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
10/22/2020Societe GeneraleUpgradeHold ➝ Buy
9/25/2020Berenberg BankInitiated CoverageBuy
8/6/2020JPMorgan Chase & Co.Reiterated RatingOverweight
6/11/2020JPMorgan Chase & Co.Reiterated RatingOverweight
6/8/2020UBS GroupDowngradeNeutral ➝ Sell
1/31/2020UBS GroupDowngradeBuy ➝ Neutral
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Sartorius Stedim Biotech logo
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Read More

Today's Range

Now: $224.44
Low: $224.44
High: $224.44

50 Day Range

MA: $270.83
Low: $214.00
High: $299.86

52 Week Range

Now: $224.44
Low: $175.12
High: $321.11

Volume

N/A

Average Volume

361 shs

Market Capitalization

N/A

P/E Ratio

52.07

Dividend Yield

0.84%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sartorius Stedim Biotech?

The following equities research analysts have issued research reports on Sartorius Stedim Biotech in the last twelve months: Barclays PLC, and Jefferies Financial Group Inc..
View the latest analyst ratings for SDMHF.

What is the current price target for Sartorius Stedim Biotech?

0 Wall Street analysts have set twelve-month price targets for Sartorius Stedim Biotech in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sartorius Stedim Biotech in the next year.
View the latest price targets for SDMHF.

What is the current consensus analyst rating for Sartorius Stedim Biotech?

Sartorius Stedim Biotech currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SDMHF.

What other companies compete with Sartorius Stedim Biotech?

Other companies that are similar to Sartorius Stedim Biotech include AddLife AB (publ), Ansell, Ansell, Asahi Intecc and BATM Advanced Communications. Learn More about companies similar to Sartorius Stedim Biotech.

How do I contact Sartorius Stedim Biotech's investor relations team?

Sartorius Stedim Biotech's physical mailing address is Zone Industrielle Les Paluds, Aubagne, Provence-Alpes-Cote-dAzur 13400. The company's listed phone number is (344) 284-5600. The official website for Sartorius Stedim Biotech is www.sartorius.com. Learn More about contacing Sartorius Stedim Biotech investor relations.